Study of Long-Term Survivors and Controls in Metastatic Pancreatic, Glioblastoma, and Small Cell Lung Cancers to Identify New Treatment Targets

What this Trial Is About

Researchers are conducting a retrospective, exploratory study involving three groups of patients who have solid tumors with poor prognosis but show either long-term or standard survival. The study focuses on metastatic pancreatic ductal adenocarcinoma, glioblastoma IDH wild-type, and extensive small cell lung cancer. The goal is to integrate data from clinical records, imaging, and multiple omics technologies to identify differences between patients with exceptional survival and those with typical outcomes, aiming to find new therapeutic targets. The study collects biological samples and clinical information from patients who survived longer than usualover 5 years for pancreatic and small cell lung cancer, and over 3 years for glioblastoma. Data from multiple molecular levels including genomic, epigenomic, proteomic, metabolomic, transcriptomic, and microbiomic analyses will be combined and analyzed using advanced bioinformatics and artificial intelligence techniques. Researchers will compare these findings with control patients who had standard survival times. Participants tumor samples and clinical data will be centralized and analyzed to identify molecular signatures associated with long-term survival. The study uses digital histology, radiomics, and multi-omics to characterize these signatures within each cancer cohort and across all groups. The primary outcome is measuring exceptional survival at 54 months. This observational study involves no treatment interventions, focusing instead on data collection and analysis to improve understanding of cancer resistance and survival.

Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis